Evidence map›Paper›PMID 40911415›Full record

ArticleCell reports2025

A single-cell framework identifies functionally and molecularly distinct multipotent progenitors in adult human hematopoiesis.

Asiri Ediriwickrema, Yusuke Nakauchi, Amy C Fan, Thomas Köhnke, Xiaoyi Hu, Bogdan A Luca, YeEun Kim, Sreejith Ramakrishnan, Margaret Nakamoto, Daiki Karigane and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. AbioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Aging and immunity: the age-old tango.Genes & development · 2025
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Asiri EdiriwickremaInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Graduate Program, Stanford University, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Yusuke NakauchiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Amy C FanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Immunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.
Thomas KöhnkeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Xiaoyi HuInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA.
Bogdan A LucaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
YeEun KimImmunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Sreejith RamakrishnanBD Biosciences, San Jose, CA 95131, USA.
Margaret NakamotoBD Biosciences, San Jose, CA 95131, USA.
Daiki KariganeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Japan Society for the Promotion of Science, Tokyo, Japan.
Miles H LindeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Immunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA.
Armon AziziInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Aaron M NewmanDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Andrew J GentlesCancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Ravindra MajetiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: rmajeti@stanford.edu.

Funding

Systems analysis of mechanisms driving response to immunotherapy in clear cell cancersU01CA264611 · NCI · STANFORD UNIVERSITY · PI Andrew J. Gentles · 2022 to 2026
$2.7M
Computational analysis of tumor ecosystems and their regulation and association with outcomesR01CA276828 · NCI · STANFORD UNIVERSITY · PI Andrew J. Gentles · 2023 to 2026
$2.4M
Human Acute Myeloid Leukemia Stem CellsR01CA251331 · NCI · STANFORD UNIVERSITY · PI MAJETI, RAVINDRA · 2020 to 2024
$1.8M
Epigenetic, Transcriptional, and Microenvironmental Determinants of Human HSC Self-RenewalR01HL142637 · NHLBI · STANFORD UNIVERSITY · PI MAJETI, RAVINDRA · 2018 to 2021
$1.6M
The prognostic landscape of gender- and ethnicity-specific immune influences on cancer outcomesR21CA238971 · NCI · STANFORD UNIVERSITY · PI GENTLES, ANDREW J. · 2019 to 2020
$374k
Single cell characterization of human acute myeloid leukemiaF32CA250304 · NCI · STANFORD UNIVERSITY · PI EDIRIWICKREMA, ASIRI · 2020 to 2022
$254k
High resolution profiling of cellular communities in the tumor microenvironmentK99CA276901 · NCI · STANFORD UNIVERSITY · PI LUCA, BOGDAN ALEXANDRU · 2023 to 2023
$170k
NCI NIH HHS F32 CA250304NCI NIH HHS K99 CA276901NCI NIH HHS R01 CA251331NCI NIH HHS R01 CA276828NCI NIH HHS R21 CA238971NCI NIH HHS U01 CA264611NHLBI NIH HHS R01 HL142637
6 · The paper itself

Abstract

Hematopoietic multipotent progenitors (MPPs) regulate blood cell production to meet the evolving demands of an organism. Adult human MPPs remain ill defined, whereas mouse MPPs are well characterized, with distinct immunophenotypes and lineage potencies. Using multi-omic single-cell analyses and functional assays, we identified distinct human MPPs within Lin-CD34+CD38dim/lo adult bone marrow with unique biomolecular and functional properties. These populations were prospectively isolated based on expression of CD69, CLL1, and CD2 in addition to classical markers like CD90 and CD45RA. We identified a CD69+ MPP with long-term engraftment and multilineage differentiation potential, a CLL1+ myeloid-biased MPP, and a CLL1-CD69- erythroid-biased MPP. We used this updated hematopoietic stem and progenitor cell (HSPC) profile to study human and mouse bone marrow cells and observe unique cell-type-specific homology between species and cell-type-specific changes associated with human aging. By identifying and functionally characterizing adult MPP sub-populations, we provide a framework for future studies in hematopoiesis.

Indexed as

HematopoiesisMultipotent Stem CellsSingle-Cell AnalysisAdultAnimalsAntigens, CDCell DifferentiationCell LineageHematopoietic Stem CellsHumansMaleMiceAntigens, CDagingbone marrowCP: Stem cell researchdifferentiationhematopoiesishematopoietic stem and progenitor cellshematopoietic stem cellsmultipotent progenitorsoligopotent progenitorssingle-cell RNA sequencing and single-cell multi-omics

Identifiers

PMID40911415
PMCPMC12532041

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.